Links at the end:
The US bought enough vaccine from Pfizer and Moderna for 100 million people, less than a third of the country. Most of our hopes were placed on AstraZeneca (Oxford), Sanofi, and Johnson & Johnson. Some analysts are now predicting that the AstraZeneca vaccine will never be approved in the US due to the tests not meeting certain FDA requirements, generally low reliability and the fact that many people who took the vaccine went on to get covid and become seriously ill--in other words, having the vaccine didn't mitigate the danger if you still caught covid. AstraZeneca seems to be changing their target to developing nations that would have difficulty handling the Pfizer and Moderna vaccines.
Sanofi has had to restart testing after failing to give patients over 50 the correct doses. It now expects to not be able to produce vaccine until 2022.
J & J has a little more hope and could finish testing in late January (we could get some early results sooner), but the fact that they are starting a new year-long trial testing a booster dose doesn't instill a lot of confidence. That may be the wrong way of looking at it, though. They may intend to follow these people for years to see how long their immunity lasts. In any event, we need to be rooting for good results from J & J.
CureVac, which should start phase 3 trials this month of its vaccine which is similar to Pfizer and Moderna's vaccine, has sold over 405 million doses to the EU, but the US has not purchased any.
Novavax is the only other company that the US has purchased vaccines from. So far the FDA has rebuffed efforts to start a phase 3 trial in the US due to questions regarding Novavax's manufacturing facility here. Novavax is going ahead with phase 3 trials in the UK and EU and may try to get approval again from the FDA this month to start trials in the US, or it has been suggested that it could submit results from the European study to the FDA for emergency approval; however, those results would likely not meet the FDA's requirements for testing on minorities.
We may have to come crawling back to Pfizer and Moderna for more vaccines, but they may already have sold as much as they can make for the foreseeable future. Got to hope that J & J and Novavax are ready to go when we run out of the Pfizer and Moderna vaccines, likely in February.
AstraZeneca, J&J COVID-19 shots must succeed to meet U.S. vaccination goal
Sanofi suffers major setback in development of a Covid-19 vaccine
EU secures 405 million doses of CureVac’s COVID-19 vaccine
The U.S. has already invested billions in potential coronavirus vaccines. Here’s where the deals stand
Novavax, swamped with FDA's manufacturing 'questions,' hopes for US coronavirus shot trial within the year
The US bought enough vaccine from Pfizer and Moderna for 100 million people, less than a third of the country. Most of our hopes were placed on AstraZeneca (Oxford), Sanofi, and Johnson & Johnson. Some analysts are now predicting that the AstraZeneca vaccine will never be approved in the US due to the tests not meeting certain FDA requirements, generally low reliability and the fact that many people who took the vaccine went on to get covid and become seriously ill--in other words, having the vaccine didn't mitigate the danger if you still caught covid. AstraZeneca seems to be changing their target to developing nations that would have difficulty handling the Pfizer and Moderna vaccines.
Sanofi has had to restart testing after failing to give patients over 50 the correct doses. It now expects to not be able to produce vaccine until 2022.
J & J has a little more hope and could finish testing in late January (we could get some early results sooner), but the fact that they are starting a new year-long trial testing a booster dose doesn't instill a lot of confidence. That may be the wrong way of looking at it, though. They may intend to follow these people for years to see how long their immunity lasts. In any event, we need to be rooting for good results from J & J.
CureVac, which should start phase 3 trials this month of its vaccine which is similar to Pfizer and Moderna's vaccine, has sold over 405 million doses to the EU, but the US has not purchased any.
Novavax is the only other company that the US has purchased vaccines from. So far the FDA has rebuffed efforts to start a phase 3 trial in the US due to questions regarding Novavax's manufacturing facility here. Novavax is going ahead with phase 3 trials in the UK and EU and may try to get approval again from the FDA this month to start trials in the US, or it has been suggested that it could submit results from the European study to the FDA for emergency approval; however, those results would likely not meet the FDA's requirements for testing on minorities.
We may have to come crawling back to Pfizer and Moderna for more vaccines, but they may already have sold as much as they can make for the foreseeable future. Got to hope that J & J and Novavax are ready to go when we run out of the Pfizer and Moderna vaccines, likely in February.
AstraZeneca, J&J COVID-19 shots must succeed to meet U.S. vaccination goal
Sanofi suffers major setback in development of a Covid-19 vaccine
EU secures 405 million doses of CureVac’s COVID-19 vaccine
The U.S. has already invested billions in potential coronavirus vaccines. Here’s where the deals stand
Novavax, swamped with FDA's manufacturing 'questions,' hopes for US coronavirus shot trial within the year
